Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

N-004

Supelco

Naloxone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C19H21NO4
Número CAS:
465-65-6
Peso molecular:
327.37
Número CE:
200-659-6
Número MDL:
MFCD00242634
Código UNSPSC:
41116107
ID de substância PubChem:
329818392
NACRES:
NA.24

grau

certified reference material

Formulário

liquid

Características

Snap-N-Spike®/Snap-N-Shoot®

embalagem

ampule of 1 mL

fabricante/nome comercial

Cerilliant®

concentração

1.0 mg/mL in methanol

técnica(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicação(ões)

forensics and toxicology

Formato

single component solution

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC=C

InChI

1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1

chave InChI

UZHSEJADLWPNLE-GRGSLBFTSA-N

Informações sobre genes

human ... OPRD1(4985) , OPRK1(4986) , OPRM1(4988)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

Naloxone is an opiate drug used to counter the effects of opioid overdose. This certified solution standard is applicable for use in LC/MS or GC/MS applications such as clinical toxicology and forensic analysis. Naloxone is sold under the trade names Narcan®, Nalone, and Narcan®ti.

Informações legais

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Narcan is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

produto relacionado

Nº do produto
Descrição
Preços

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

IMPN-007-04

Naloxone N-oxide solution, 100 μg/mL in acetonitrile: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

N-063

Naloxone-D5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-924

Nalorphine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

N-115

Naloxone-D5 solution, 1.0 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-004S

Naloxone solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Palavra indicadora

Danger

Classificações de perigo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órgãos-alvo

Eyes,Central nervous system

Código de classe de armazenamento

3 - Flammable liquids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

49.5 °F - closed cup

Ponto de fulgor (°C)

9.7 °C - closed cup

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Anne M Neumann et al.
Journal of addictive diseases, 32(1), 68-78 (2013-03-14)
Patients with opioid addiction who receive prescription opioids for treatment of nonmalignant chronic pain present a therapeutic challenge. Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone. At the 6-month follow-up examination, 26 (48.1%)
R Terry Furst
Journal of addictive diseases, 32(1), 53-67 (2013-03-14)
This study explores strategies that Suboxone misusers utilize while in drug treatment. Ethnographic interviews were conducted with 14 patients who had cycled in and out of Suboxone treatment. The objective of the study is to identify strategies implemented by patients
Jason Boland et al.
Clinical medicine (London, England), 13(2), 149-151 (2013-05-18)
Opioids can induce respiratory depression by invoking a centrally mediated decrease in involuntary respiratory rate, which in severe cases can cause a decrease in oxygen saturation. If respiratory depression is opioid induced, both low respiratory rate and low oxygen saturation
The opioid system is involved in the analgesic effects of Tactivin.
A N Inozemtsev et al.
Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 450, 130-133 (2013-07-04)
Sarah Bowman et al.
The American journal of medicine, 126(7), 565-571 (2013-05-15)
Addiction to prescription opioids is prevalent in primary care settings. Increasing prescription opioid use is largely responsible for a parallel increase in overdose nationally. Many patients most at risk for addiction and overdose come into regular contact with primary care
Exibir todos os documentos relacionados

Artigos

Benefits of Ascentis Express Phenyl-Hexyl over Biphenyl for the Separation of Pain Management Opiates

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica